01/17/2006 19:33

Remarks

FOLEY HOAG LLP

Claims 1-11, 20-30, 48, 50, and 51 are pending in the application.

Claims 2, 3, 5, 6, 22, 24, 25, 50 and 51 have been amended. No new matter has been added. Support for the claim amendments and new claims can be found throughout the application.

Importantly, the claim cancellations and amendments should not be construed to be an acquiescence to any of the claim rejections. Rather, the cancellations of and amendments to the claims are being made solely to expedite the prosecution of the above-identified application. The Applicants expressly reserve the right to further prosecute the same or similar claims in subsequent patent applications claiming the benefit of priority to the instant application. 35 USC § 120.

Applicants thank the Examiner for removing the rejections for lack of written description, lack of enablement and lack of novelty. Further, Applicants thank Examiner for the helpful teleconference of December 13, 2005.

Claim Rejections Based on 35 USC § 112¶2 - Indefiniteness

Claims 1-11, 20-30, 48, 50 and 51 were rejected under 35 USC § 112¶2, based on the Examiner's contention that the claim(s) are indefinite for failing to particularly point out and distinctly claim the subject matter which Applicants regard as the invention. To better organize the Applicant's traverses of the Examiner's rejections under 35 USC § 112¶2, they are set forth below in paragraphs labeled according to the format used by the Examiner in the Office Action.

Claim Rejection 3a.

The Examiner contends that the rejection of paragraph 7b from the March 28, 2005 Office Action still applies. Specifically, the Examiner contended in that Office Action that the definitions of the terminal group "E" of claim 1 inconsistently include definitions of groups which are not terminal groups and in which the valency of "E" would be incorrect. Applicants note that E is the terminal group at the end of a substituent which is single bonded to a carbon on the aromatic ring, i.e., -E. Thus, when E is "carbonyl" or "sulfonyl", that means the substituent

- 14 -B3135553.1

is -C(=O)- or -C(=S)-. Accordingly, Applicants urge that claims 1, 2, 8, 10, 20, 22, 27, 29 and 48 are definite.

Claim Rejection 3b.

The Applicants have amended claim 2 to make it consistent with claim 1 from which it depends.

Claim Rejection 3c.

The Applicants have amended claim 3 to add the term to which "is optionally present and if present" refers.

Claim Rejection 3d.

The Applicants have amended claim 22 to add the term to which "is optionally present and if present" refers.

Claim Rejection 3e.

Applicants have rewritten claims 50 and 51 as independent claims incorporating a relevant definition taken from the claims from which they originally depended.

Claim Rejection 3f.

Applicants have amended claims 5, 6, 24 and 25 to clarify that the V referred to is the remaining Lewis base.

Accordingly, the Applicants respectfully request with drawal of all of the rejections based on 35 USC \S 112 \P 2 for indefiniteness.

B3135553.1 - 15 -

Conclusion

In view of the above amendments and remarks, it is believed that the pending claims are in condition for allowance. Therefore, the Applicants respectfully request reconsideration and withdrawal of the pending rejections. If a telephone conversation with Applicants' Attorney would expedite prosecution of the above-identified application, the Examiner is urged to contact the undersigned.

Patent Group FOLEY HOAG LLP 155 Seaport Boulevard Boston, MA 02210

(617) 832-1000 (617) 832-7000 (FAX)

Date: January 17, 2006

Respectfully submitted. FOLEY HOAG ILP

Jernifer A. Zarutskie, Ph.D. Registration No. 50,558

Attorney for Applicants